The Institute for Clinical and Economic Review and its controversial “one-size-fits-all” value framework are a direct threat to patients living with rare diseases, an independent report warns.
To fix its broken value framework, ICER should stop using the QALY, or quality-adjusted life year, in its value framework and cost assessments.
Patients living with migraine need access to effective treatments. ICER has begun its process of evaluating treatments for acute migraine.
The Institute for Clinical and Economic Review (ICER) is floating a power grab at the Food and Drug Administration to deny patients access to innovation.
Thousands of young boys living with Duchenne Muscular Dystrophy, a rare and fatal disease, could be denied access to treatment, due to a new ICER report.
We have an important message for ICER: Patients are not a number. Patients living with depression and multiple sclerosis have the same right to access treatments as anyone else.
An obscure health care cost evaluator could deliver a devastating blow to patients living with multiple sclerosis this week, as it evaluates a promising new treatment for the autoimmune disorder.…
When Kate was diagnosed with cervical cancer, her doctors were optimistic. Boston Globe: Kate Weissman said that by refusing to pay for proton beam therapy, UnitedHealthcare “put the bottom line…
With the backing of multi-billion-dollar insurance companies, ICER is conducting an analysis of a treatment for secondary progressive multiple sclerosis.
The debate over former vice presidential candidate Sarah Palin’s inaccurately named “death panels” has come to Massachusetts. The debate centers on a measure of cost-effectiveness for health care, which assigns…